反应停对恶性血液病患者血清肿瘤坏死因子受体的影响及临床意义

The effect of thalidomide on blood serum soluble tumor necrosis factor receptor level and its clinical significance in patients with hematological malignancies

目的 :观察反应停对恶性血液病患者血清肿瘤坏死因子受体 (sTNFR)的影响及不良反应。方法 :对 4 6例恶性血液病患者随机分化疗组和化疗加反应停组 ,采用夹心酶联法分别测定两组患者治疗前后血清sTNFR水平 ,并以 18例正常人作对照。结果 :治疗前两组患者血清sTNFR水平均显著升高 ,差异无统计学意义 ,与正常对照组差异有统计学意义 (均P <0 .0 1) ,治疗后两组患者血清sTNFR水平比较差异有统计学意义 (P <0 .0 1) ,化疗加反应停组患者血清sTNFR水平治疗前后差异有统计学意义 (P <0 .0 1)。结论 :反应停联合化疗可进一步降低sTNFR ,提高疗效 ,不良反应少。

Objective:To observe the effect of thalidomide on blood serum soluble tumour necrosis factor level and its clincal significance in patients with hematological malignancies.Method:Forty-six patients were randomly separated into two groups.One group was treated with chemotherapy,the other was treated with chemotherapy plus thalidomide.Blood serum levels of sTNFR were detected with sandwich enzyme immunoassay in 46 patients.18 normal subjects that were used as controls.Result:The blood serum levels of sTNFR in 46 patients were obviously increased,showing significantly difference compared with normal controls(P<(0.01) .The blood serum levels of sTNFR in chemotherapy plus thalidomide patients were obviously decreased ,showing significantly difference compared with that before therapy and chemotherapy solely(P<(0.01)).Conclusion:Thalidomide plus chemotherapy obviously resulted in decreasing of sTNFR, improved the curative effect and had slight side-effect.sTNFR can be used as an effective tool to evaluate the curative effect of thalidomide.